GPX4
脂质过氧化
药理学
细胞凋亡
抗氧化剂
化学
背景(考古学)
程序性细胞死亡
生物化学
生物
谷胱甘肽过氧化物酶
超氧化物歧化酶
古生物学
作者
Yujie Wu,Yansu Ji,Xin Jin,Guangjing Xu,Xiaoyu Wang,Saisai Song,Rui Li,Yuhan Wang,Rui Liu,Zheng Li
摘要
OBJECTIVES: Shuxuetong injection (SXT) treats cerebral ischemic injury by inhibiting apoptosis. However, the specific active ingredient responsible for this effect and its mechanism of action remain unclear. METHODS: In previous research, we identified the small peptide YLKTT in SXT, which has shown protective effects on astrocytes subjected to oxygen-glucose deprivation/reoxygenation (OGD/R). In this study, we utilized transcriptomics technology to predict the specific target genes and pathways of YLKTT in the context of stroke treatment. We further validated these predictions through RT-PCR, lipid peroxidation assays, Western blotting, and other related methods. KEY FINDINGS: The transcriptomics results indicated that YLKTT could further alleviate ischemia-reperfusion injury by inhibiting ferroptosis, with the specific pathway likely involving the regulation of glutathione peroxidase 4 (GPX4) by ACSL4 and SLC7A11. Experimental results demonstrated that YLKTT interfered with the SLC7A11/GPX4 and ACSL4/GPX4 pathways, thereby enhancing antioxidant capacity, inhibiting the accumulation of lipid peroxidation, and ultimately reversing OGD-induced ferroptosis. Additionally, erastin significantly reduced SLC7A11 mRNA and protein levels and decreased GPX4 levels, while YLKTT was able to reverse these changes. CONCLUSIONS: YLKTT can exert anti-ferroptosis effects through the ACSL4/GPX4 and SLC7A11/GPX4 pathways, thereby improving the treatment of cerebral ischemic injury.
科研通智能强力驱动
Strongly Powered by AbleSci AI